Confirmatory Phase 3 trial replicating MAPP1 findings. 71.2% of participants no longer met PTSD diagnostic criteria vs 47.6% placebo. Patients had average 16-year treatment-resistant PTSD history.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial, Nature Medicine (2023)